Status:
ENROLLING_BY_INVITATION
18F-MFBG Cardiac Imaging for Heart Failure Administration
Lead Sponsor:
Sichuan Provincial People's Hospital
Conditions:
Rest Gated Myocardial Perfusion Imaging in Heart Failure
Eligibility:
All Genders
18-80 years
Brief Summary
The clinical feasibility of 18F-FMBG cardiac PET imaging will be observed in sympathetic nervous system activity in patients with heart failure, predicted cardiac events, guided ICD implantation, and ...
Detailed Description
This is a prospective, single-center clinical study, using18F-meta-fluorobenzylguanidine (18F-MFBG) cardiac PET imaging to present the sympathetic nerve status in heart failure, including ICD implanta...
Eligibility Criteria
Inclusion
- 1\. Clinically confirmed patient with chronic heart failure, LVEF ≤ 40%, cardiac function NYHA 2-3 grade, survival period greater than 1 year, evaluated by the Heart Failure Center of Sichuan Provincial People's Hospital.
- 2\. Chronic heart failure patients were evaluated by the Cardiology Department of Sichuan Provincial People's Hospital 5-10 days before ICD implantation.
- 3\. All patients above have signed an informed consent form.
Exclusion
- 1\. Heart failure, heart function NYHA levels ⅠOR Ⅳ.
- 2\. The patient has already implanted ICD or CRT.
- 3\. Heart transplant patients.
- 4\. Patients with malignant tumors.
- 5\. Heart valve disease.
- 6\. Myocardial infarction occurred within the past three months.
- 7\. The patient has contraindications for ICD implantation surgery.
- 8\. The patient does not cooperate or is unwilling to conduct the study.
Key Trial Info
Start Date :
January 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2026
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT06149195
Start Date
January 1 2024
End Date
December 31 2026
Last Update
January 24 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Zhi Ling Ding
Chengdu, Sichuan, China, 610072